The present invention relates to novel triazolo-pyridines of the formula I ##STR00001## wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R.sup.2 is selected from the group consisting of hydrogen, (C.sub.1 C.sub.6)alkyl or other suitable substituents; R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1 C.sub.6)alkyl or other suitable substituents; s is an integer from 0 5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.